lefamulin (Xenleta)
Jump to navigation
Jump to search
Indications
- community-acquired pneumonia in adults[1][2]
Contraindications
- not recommended during pregnncy
Dosage
- oral (600 mg every 12 hours)
- intracenous (150 mg every 12 hours)[2]
Antimicrobial activity
- Streptococcus pneumoniae
- Staphylococcus aureus (MSSA)
- Haemophilus influenzae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae[2]
Adverse effects
Mechanism of action
- semisynthetic pleuromutilin antibiotic
Notes
- projected wholesale acquisition price:
More general terms
References
- ↑ 1.0 1.1 1.2 FDA News Release. Aug 19, 2019 FDA approves new antibiotic to treat community-acquired bacterial pneumonia. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia
Brooks M FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP. Medscape - Aug 19, 2019. https://www.medscape.com/viewarticle/917020 - ↑ 2.0 2.1 2.2 2.3 2.4 Alexander E, Goldberg L, Das AF et al Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia. The LEAP 2 Randomized Clinical Trial. JAMA. Published online September 27, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31560372 https://jamanetwork.com/journals/jama/fullarticle/2752331
Malani PN Lefamulin - A New Antibiotic for Community-Acquired Pneumonia. JAMA. Published online September 27, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31560367 https://jamanetwork.com/journals/jama/fullarticle/2752330
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25185057
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86346053
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=90465828
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=134692783
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=138112629